Drug Testing: Process and Settings in Addiction Treatment Webinar (1 CME)

5 (3 votes)

Registration Closed

This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. It will allow physicians to determine clearly how to choose and schedule a test, and respond to test results. It will also allow physicians to recognize the specific guidance warranted by different settings and levels of care including early intervention, outpatient services, intensive outpatient/partial hospitalization services, residential/inpatient care, medically management intensive inpatient services, and opioid treatment services. This webinar is intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population.

Ken Freedman, MD, MS, MBA, FACP, AGAF, DFASAM

Medical Director, Aetna

Ken has been a dedicated ASAM member and officer (CT, MA, and nationally) for the past 22 years. His commitment has been demonstrated by most recently serving as National Treasurer & Finance Council Chair (since 2019) and Quality Improvement Council Chair (since 2019). He has also served on The ASAM Criteria Strategy Steering Committee and the CEO Search Committee. Previous roles have included: Regional III Director (2013-2018), Finance Committee member (since 2013), Ethics Committee member (since 2015 and Chair 2018-2019), Quality Improvement Council member (since 2016), MA officer (Treasurer and Secretary), and CT officer (President, Vice-President, and Secretary/Treasurer).

Currently, he works as both a Medical Director for Aetna (a CVS Health Company) and as Physician Consultant for The Recovery Research Network (TRRN). His previous leadership roles have also included MA Public Health Hospitals’ system quality chief, public health hospital CMO (Lemuel Shattuck Hospital in Boston), director of two outpatient MAT programs, Clinical Professor of Medicine at Tufts University School of Medicine and Adjunct Clinical Associate Professor of Psychiatry at the University of Massachusetts Medical School. He is board-certified in addiction medicine, internal medicine and gastroenterology, and maintains membership in the AMA, ACP, ACG, and AGA. Ken’s professional commitment is to help move health care delivery toward the integration of medical care and substance use disorders in respectful and innovative ways.

ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives
1. Identify the fundamental components of the process of drug testing in addiction treatment.
2. Determine how to appropriately select the type of test for each patient, and how to respond to various test results.
3. Analyze the importance of and guidance around test scheduling and frequency.
4. Recognize the specific guidance warranted by drug testing in different settings and levels of care.